Rallybio Corporation (RLYB)

NCM – Real Time Price. Currency in USD

14.03

+0.03 (0.21%)

At close: May 12, 2026, 4:00 PM EDT

13.63

-0.40 (-2.88%)

Pre-market: May 13, 2026, 6:07 AM EDT

04.03.2026

Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Rallybio Corporation (NasdaqCM: RLYB) and Candid Therapeutics, Inc. Upon completion of the proposed transaction, Rallybio shareholders are expected to own approximately 3.65% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the me.

02.03.2026

Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript

02.03.2026

Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism

Rallybio Corporation (NASDAQ: RLYB) shares are up Monday following a merger agreement with Candid Therapeutics Inc.

02.03.2026

RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Deal for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Rallybio Corporation (NASDAQ: RLYB) and Candid Therapeutics, Inc. Upon completion of the proposed transaction, Rallybio shareholders are expected to own approximately 3.65% of the combined company. Halper Sadeh encourages Rallybio shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpers.

02.03.2026

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

NEW HAVEN, Conn. & SAN DIEGO--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) ("Rallybio") and Candid Therapeutics, Inc. ("Candid"), a global clinical-stage biotechnology company advancing a leading portfolio of T-cell engager ("TCE") therapeutics for autoimmune diseases, today announced that they have entered into a definitive agreement pursuant to which Rallybio will acquire Candid through a merger transaction (the "Merger"). Upon completion of the Merger, the combined company expects to.

02.03.2026

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

17.02.2026

Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026

Complement-mediated diseases arise from overactivation or dysfunction of the complement system, a part of the innate immune system.

Videos

No Data

There is no data to display

Press releases

04.03.2026

Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB

02.03.2026

RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Deal for its Shareholders

02.03.2026

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

02.03.2026

Rallybio Corporation (RLYB)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Rallybio Corporation (RLYB)

Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB

Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript

Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism

RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Deal for its Shareholders

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026

Videos

No Data

Press releases

Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB

RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Deal for its Shareholders

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB

Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript

Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism

RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Deal for its Shareholders

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026

Videos

No Data

Press releases

Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB

RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Deal for its Shareholders

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Search stocks

Rallybio Corporation (RLYB)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Rallybio Corporation (RLYB)

Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB

Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript

Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism

RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Deal for its Shareholders

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026

Videos

No Data

Press releases

Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB

RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Deal for its Shareholders

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB

Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript

Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism

RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Deal for its Shareholders

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026

Videos

No Data

Press releases

Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB

RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Deal for its Shareholders

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement